文献リスト

1) Montano-Loza AJ, Carpenter HA, Czaja AJ. Clinical significance of HLA DRB103-DRB104 in type 1 autoimmune hepatitis. Liver Int. 2006; 26: 1201-8

2) Agarwal K, Czaja AJ, Donaldson PT. A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens. 2007; 69: 227-35

3) Berry PA, Smith-Laing G. Hepatitis A vaccine associated with autoimmune hepatitis. World J Gastroenterol. 2007; 13: 2238-9

4) Chamberlain MC, Schwarzenberg SJ, Akin EU, et al. Minocycline-induced autoimmune hepatitis with subsequent cirrhosis. J Pediatr Gastroenterol Nutr. 2006; 42: 232-5

5) Alla V, Abraham J, Siddiqui J, et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol. 2006; 40: 757-61

6) Tokumoto Y, Onji M. Acute-onset autoimmune hepatitis. Intern Med. 2007; 46: 1-2

7) Hofer H, Oesterreicher C, Wrba F, et al. Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol. 2006; 59: 246-9

8) Miyake Y, Iwasaki Y, Terada R, et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases. Aliment Pharmacol Ther. 2006; 23: 1347-53

9) Csepregi A, Rocken C, Treiber G, et al. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol. 2006; 12: 1362-6

10) Wiegand J, Schuler A, Kanzler S, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005; 25: 927-34

11) Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci. 2006; 51: 968-75

12) Heneghan MA, Allan ML, Bornstein JD, et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol. 2006; 45: 584-91

13) Tamori A, Shinzaki M, Kosaka S, et al. Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. Liver Int. 2007; 27: 95-100

14) Miyake Y, Iwasaki Y, Terada R, et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol. 2005; 43: 951-7

15) Montano-Loza AJ, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int. 2007; 27: 507-15

16) Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007; 102: 1005-12

17) Al-Chalabi T, Heneghan MA. Remission in autoimmune hepatitis: what is it, and can it ever be achieved？ Am J Gastroenterol. 2007; 102: 1013-5

18) Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci. 2005; 50: 547-51

19) Tan P, Marotta P, Ghent C, et al. Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. Liver Int. 2005; 25: 728-33

20) Meza-Junco J, Montano-Loza AJ, Martinez-Benitez B, et al. Hepatocellular carcinoma in patients with autoimmune liver diseases: Two case reports and literature review. Ann Hepatol. 2007; 6: 122-6

21) Al-Chalabi T, Boccato S, Portmann BC, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006; 45: 575-83

22) Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006; 43: 532-8

23) Miyake T, Miyaoka H, Abe M, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res. 2006; 36: 139-42

24) Oettinger R, Brunnberg A, Gerner P, et al. Clinical features and biochemical data of Caucasian children at diagnosis of autoimmune hepatitis. J Autoimmune. 2005; 24: 79-84

25) 松井 陽. 小児自己免疫性肝炎の全国調査. In: 大西三朗, 編. 厚生労働科学研究費補助金(難治性疾患克服研究事業) 難治性の肝・胆道疾患に関する調査研究 平成18年度総括・分担研究報告書. 2007. p. 34-5

26) Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001; 33: 544-53

27) Sogo T, Fujisawa T, Inui A, et al. Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis. Hepatol Res. 2006; 34: 187-92

28) Banerjee S, Rahhal R, Bishop WP. Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2006; 43: 353-6

29) Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr. 2006; 43: 635-9

30) Buchel E, Van Steenbergen W, Nevens F, et al. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol. 2002; 97: 3160-5

31) Samuel D, Riordan S, Strasser S, et al. Severe autoimmune hepatitis first presenting in the early post partum period. Clin Gastroenterol Hepatol. 2004; 2: 622-4

32) Schramm C, Herkel J, Beuers U, et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol. 2006; 101: 556-60

33) Heurgue A, Vitry F, Diebold MD, et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol. 2007; 31: 17-25

34) Alric L, Thebault S, Selves J, et al. Characterization of overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis according to antimitochondrial antibodies status. Gastroenterol Clin Biol. 2007; 31: 11-6

35) Silveira MG, Talwalkar JA, Angulo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007; 102: 1244-50

36) Chazouilleres O, Wendum D, Serfaty L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2006; 44: 400-6

37) Poupon R, Chazouilleres O, Corpechot C, et al. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006; 44: 85-90

38) Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006; 12: 1813-24

39) Yao H, Michitaka K, Tokumoto Y, et al. Recurrence of autoimmune hepatitis after liver transplantation without elevation of alanine aminotransferase. World J Gastroenterol. 2007; 13: 1618-21

40) Rodriguez-Diaz Y, Reyes-Rodriguez R, Dorta-Francisco MC, et al. De novo autoimmune hepatitis following liver transplantation for primary biliary cirrhosis. Transplant Proc. 2006; 38: 1467-70

41) Berardi S, Lodato F, Gramenzi A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis？ Gut. 2007; 56: 237-42

42) Miyagawa-Hayashino A, Haga H, Egawa H, et al. Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation. Transplantation. 2004; 78: 128-35

43) Aguilera I, Sousa JM, Gavilan F, et al. Glutathione S-transferase T1 genetic mismatch is a risk factor for de novo immune hepatitis in liver transplantation. Transplant Proc. 2005; 37: 3968-9

44) Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(＋)CD25(＋) regulatory T-cells in autoimmune liver disease. J Hepatol. 2004; 41: 31-7

45) Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4＋ CD25＋ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmune. 2005; 25: 63-71

46) Longhi MS, Hussain MJ, Mitry RR, et al. Functional study of CD4＋CD25＋ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006; 176: 4484-91

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp